Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | LTA4H | P09960 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.50 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10575040 | 0.98 | NQO1 (0.64) | NQO1MAPTRAB9AL3MBTL1TSHR | |
| SCHEMBL12251519 | 0.94 | MAPT (0.66) | NQO1MAPTRAB9AL3MBTL1SIGMAR1 | |
| SCHEMBL10570997 | 0.94 | RAB9A (0.61) | NQO1MAPTRAB9AL3MBTL1TSHR | |
| SCHEMBL7582735 | 0.92 | MAPT (0.64) | NQO1MAPTRAB9AL3MBTL1TSHR | |
| SCHEMBL12251523 | 0.92 | MAPT (0.64) | NQO1MAPTRAB9AL3MBTL1TSHR | |
| SCHEMBL615024 | 0.92 | MAPT (0.64) | NQO1MAPTRAB9AL3MBTL1TSHR | |
| SCHEMBL8521940 | 0.92 | MAPT (0.64) | NQO1MAPTRAB9AL3MBTL1TSHR | |
| SCHEMBL170615 | 0.92 | MAPT (0.64) | NQO1MAPTRAB9AL3MBTL1TSHR | |
| SCHEMBL39534 | 0.92 | MAPT (0.64) | NQO1MAPTRAB9AL3MBTL1TSHR | |
| SCHEMBL8986268 | 0.91 | NQO1 (0.61) | NQO1MAPTRAB9AL3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8691845-B2 | Tetra-O-substituted butane-bridge modified NDGA derivatives, their synthesis and pharmaceutical use | ERIMOS PHARMACEUTICALS LLC (US) | 2014-04-08 | — | — | US | disclosed |
| US-20130053378-A1 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMACEUTICAL USE | ERIMOS PHARMACEUTICALS LLC (US) | 2013-02-28 | — | — | US | disclosed |
| US-8232277-B2 | Tetra-O-substituted butane-bridge modified NDGA derivatives, their synthesis and pharmaceutical use | ERIMOS PHARMACEUTICALS LLC (US) | 2012-07-31 | — | — | US | disclosed |
| US-20090306070-A1 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMACEUTICAL USE | ERIMOS PHARMACEUTICALS LLC (US) | 2009-12-10 | — | — | US | disclosed |
| EP-2076125-A2 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMACEUTICAL USE | Erimos Pharmaceuticals LLC (US) | 2009-07-08 | — | — | EP | disclosed |
| WO-2008042921-A2 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMACEUTICAL USE | ERIMOS PHARMACEUTICALS LLC (US) | 2008-04-10 | — | — | WO | disclosed |
| US-4834905-A | LIQUID CRYSTAL DIELECTRICS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1989-05-30 | — | — | US | disclosed |
| US-4627933-A | ESTERS, ETHERS, NITRICES, HALIDES, OR HYDROCARBONS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1986-12-09 | — | — | US | disclosed |
| EP-0104327-A2 | Use of cyclic derivatives as components of liquid cristals | MERCK PATENT GmbH (DE) | 1984-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306070-A1 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMACEUTICAL USE | PTGES, HPGDS, HPGD | NQO1 933/4885MAPT 315/4885RAB9A 3064/4885 |
| US-20130053378-A1 | TETRA-O-SUBSTITUTED BUTANE-BRIDGE MODIFIED NDGA DERIVATIVES, THEIR SYNTHESIS AND PHARMACEUTICAL USE | PTGES, HPGDS, HPGD | NQO1 933/4885MAPT 315/4885RAB9A 3064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.